Literature DB >> 1532319

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

B Dahlöf1, K Pennert, L Hansson.   

Abstract

This is a metaanalysis of all available studies as of December 1990 that have evaluated the effect of antihypertensive pharmacologic therapy on left ventricular structure examined by echocardiography. We applied preset inclusion criteria to the analysis. A total of 109 studies comprising 2357 patients (28% previously untreated) with an average age of 49 years (range 30 to 71) were included. Overall left ventricular mass (LVM) was reduced by 11.9% [95% confidence interval (CI) 10.1 to 13.7] in parallel with a reduction of mean arterial pressure of 14.9% (CI 14 to 15.8). To differentiate between first-line therapies and to adjust for differences between studies, we performed ANCOVA. Angiotensin converting enzyme (ACE) inhibitors reduced LVM by 15% (CI 9.9 to 20.1), beta-blockers by 8% (CI 4.8 to 11.2), calcium antagonists by 8.5% (CI 5.1 to 11.8), and diuretics by 11.3% (CI 5.6 to 17). When we calculated LVM using the same formula for all studies the absolute reductions in grams were 44.7 g with ACE inhibitors, 22.8 g with beta-blockers, 26.9 g with calcium antagonists, and 21.4 g with diuretics. Except for diuretics, all therapies mainly affected wall thickness, while diuretics predominantly reduced ventricular diameter. In conclusion, this metaanalysis shows that ACE inhibitors, beta-blockers, and calcium antagonists all reduce LVM by reversing wall hypertrophy, and that the effect is most pronounced with ACE inhibitors. Conversely, diuretics reduce LVM mainly through a reduction of left ventricular volume. Based on these data, we hypothesize that ACE inhibitors are more effective than other first-line therapies in reducing LVM. However, this theory and its possible prognostic implications need to be evaluated in controlled prospective trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532319     DOI: 10.1093/ajh/5.2.95

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  108 in total

Review 1.  Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives?

Authors:  D J Sheridan; M P Kingsbury; N A Flores
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  [Reserpine-diuretic combinations in therapy of arterial hypertension. Current considerations].

Authors:  M Siepmann; W Kirch
Journal:  Med Klin (Munich)       Date:  1998-12-15

3.  Left ventricular hypertrophy: unresolved issues.

Authors:  J A Schoenberger
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 4.  Angiotensin converting enzyme inhibition: from viper to patient.

Authors:  M Komajda; M C Wimart
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

Review 5.  Epidemiology of risk factors for hypertension: implications for prevention and therapy.

Authors:  M Kornitzer; M Dramaix; G De Backer
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 6.  Selective versus nonselective beta adrenoceptor antagonists in hypertension.

Authors:  L M Van Bortel; A J Ament
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

7.  Heart failure and cardiac hypertrophy.

Authors:  J Eduardo Rame; Daniel L Dries
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

Review 8.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

Review 9.  The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Authors:  P Sleight
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 10.  The Hypertension in the Very Elderly Trial (HYVET). Rationale, methodology and comparison with previous trials.

Authors:  C J Bulpitt; A E Fletcher; A Amery; J Coope; J G Evans; S Lightowlers; K O'Malley; A Palmer; J Potter; P Sever
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.